Home > Keywords >
Catalog | name | Description | price |
---|---|---|---|
R-R-2852 | Crotedumab CAS No.1452387-69-7 | Crotedumab (REGN1193)/CAS No.1452387-69-7 is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes. | price> |
R-C-1153 | SU6656 cas:330161-87-0 | SU6656 is a potent and selective dual inhibitor of Src family kinases and Aurora kinase.SU6656 modulates CTGF(connective tissue growth factor)expression in an ERK-dependent manner.SU6656 induces caspase-independent cell death in FRO anaplastic thyroid carcinoma cells and therapeutic synergy in human synovial sarcoma growth,invasion and angiogenesis in vivo. | price> |
R-R-2853 | VU0453379 CAS No.1638646-27-1 | VU0453379/CAS No.1638646-27-1 is a highly selective and central nervous system (CNS) penetrant positive allosteric modulator (PAM) of glucagon-like peptide-1R (GLP-1R) with an EC50 of 1.3 μM. | price> |
R-C-1154 | BS-181 CAS:1397219-81-6 | BS-181 is a highly selective CDK inhibitor for CDK7 with an IC(50)of 21 nmol/L. Testing of other CDKs as well as another 69 kinases showed that BS-181 only inhibited CDK2 at concentrations lower than 1 micromol/L,with CDK2 being inhibited 35-fold less potently(IC(50) 880 nmol/L)than CDK7.In MCF-7 cells,BS-181 inhibited the phosphorylation of CDK7 substrates,promoted cell cycle arrest and apoptosis to inhibit the growth of cancer cell lines,and showed antitumor effects in vivo. | price> |
R-R-2854 | GLP-1R agonist 4 CAS No.2401894-26-4 | GLP-1R agonist 4/CAS No.2401894-26-4 is a potent agonist of GLP-1R. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 4 has the potential for the research of diabetes (extracted from patent WO2019239319A1, compound 96). | price> |
R-C-1155 | PLX647 CAS: 873786-09-5 | 20pecific dual FMS and KIT kinase inhibitor,with IC50s of 28 and 16 nM, respectively.PLX647 shows selectivity for FMS and KIT over a panel of 400 kinases at a concentration of 1 μM except FLT3 and KDR(IC50s=91 and 130 nM, respectively). | price> |
R-R-2855 | Exendin (5-39) CAS No.196109-27-0 | Exendin (5-39)/CAS No.196109-27-0 is a potent glucagon-like peptide 1 (GLP-1) receptor antagonist. Exendin (5-39) improves memory impairment in β-amyloid protein-treated rats. | price> |
R-C-1156 | L-701,324 CAS:142326-59-8 | L-701,324 is a potent and selective NMDA/glycine receptor antagonist.L-701,324 exhibits a beneficial action in the animal model of parkinsonian rigidity.Pre-treatment with L-701,324 improves pharmacosensitivity in a mouse kindling model. | price> |
R-R-2856 | HAEGTFTSD CAS No.926018-45-3 | HAEGTFTSD/CAS No.926018-45-3 is a 9-residue peptide of human GLP-1 peptide or GLP-1(7-36), amide (HY-P0054A). GLP-1(7-36), amide is a physiological incretin hormone that stimulates insulin secretionin a glucose-dependant manner. | price> |
R-C-1157 | CIQ CAS:486427-17-2 | CIQ is a GluN2C/GluN2D subunit-selective NMDA receptor potentiator,which reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice.The facilitation of GluN2C/GluN2D-containing receptors may serve as an important therapeutic strategy for treating positive and cognitive symptoms in schizophrenia. | price> |
R-R-2857 | HAEGTFTSDVS CAS No.864915-61-7 | HAEGTFTSDVS/CAS No.864915-61-7 is the first N-terminal 1-11 residues of GLP-1 peptide. | price> |
R-C-1158 | Pexidartinib (PLX-3397) CAS:1029044-16-3 | Pexidartinib(PLX-3397)is a potent, orally active,selective, and ATP-competitive colony stimulating factor 1 receptor(CSF1R or M-CSFR)and c-Kit inhibitor,with IC50s of 20 and 10 nM respectively.Pexidartinib(PLX-3397) exhibits 10- to 100-fold selectivity for c-Kit and CSF1R over other related kinases.Pexidartinib(PLX-3397)induces cell apoptosis and has anti-tumor activity. | price> |
R-R-2858 | GLP-1R agonist 3 CAS No.2428640-18-8 | GLP-1R agonist 3/CAS No.2428640-18-8 is a potent agonist of GLP-1R. GLP-1R agonist 3 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 3 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 1). | price> |
R-C-1159 | omarigliptin CAS:1226781-44-7 | Omarigliptin(MK-3102)is a competitive,reversible inhibitor of DPP-4(IC50=1.6 nM,Ki=0.8nM).It is highly selective over all proteases tested (IC50>67 μM), including QPP,FAP,PEP,DPP8,and DPP9 and has weak ion channel activity (IC50>30 μM at IKr,Caγ1.2,and Naγ1.5). | price> |
R-R-2859 | Glucagon receptor antagonists-1 CAS No.503559-84-0 | Glucagon receptor antagonists-1/CAS No.503559-84-0 is a highly potent glucagon receptor antagonist. | price> |
R-C-1160 | Anacetrapib (MK-0859) CAS:875446-37-0 | Anacetrapib,also known as MK-0859,is a CETP inhibitor being developed to treat hypercholesterolemia(elevated cholesterol levels)and prevent cardiovascular disease. | price> |
R-R-2860 | GCGR antagonist 2 CAS No.280134-25-0 | GCGR antagonist 2/CAS No.280134-25-0, a Furan-2-carbohydrazide, is an orally active glucagon receptor antagonist. GCGR antagonist 2 binds to hGluR with an Kd value of 2.3 nM, and inhibits rat receptor with an IC50 value of 0.43 nM. GCGR antagonist 2 inhibits glucagon-stimulated glycogenolysis. | price> |
R-C-1161 | Felbamate CAS:25451-15-4 | Felbamate(W-554)is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate(NMDA). | price> |
R-R-2861 | Exendin-3/4 (59-86) CAS No.1263874-37-8 | Exendin-3/4 (59-86)/CAS No.1263874-37-8 is a Exendin-4 peptide derivative. | price> |
R-C-1162 | BMS-687453 CAS:1000998-59-3 | BMS-687453 is a potent and selective peroxisome proliferator activated receptor (PPAR)alpha agonist. with an EC(50)of 10 nM for human PPARalpha and approximately 410-fold selectivity vs human PPARgamma in PPAR-GAL4 transactivation assays.BMS-687453 demonstrated an excellent pharmacological and safety profile in preclinical studies and thus was chosen as a development candidate for the treatment of atherosclerosis and dyslipidemia. | price> |